查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1985891

全球細胞治療用人源原料市場：市場規模、佔有率和趨勢分析（按產品、最終用途和地區分類），細分市場預測（2026-2033 年）

Cell Therapy Human Raw Materials Market Size, Share & Trends Analysis Report By Product, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

細胞治療用人源原料市場概況

2025年全球用於細胞治療的人類來源原料市場價值為43.7億美元，預計到2033年將達到167.9億美元，2026年至2033年的複合年成長率為18.44%。

癌症、糖尿病和自體免疫疾病等慢性疾病的日益普遍，再生醫學和個人化醫療需求的成長，研發活動的活性化以及投資的擴大，預計將在預測期內推動細胞治療用人源原料市場的發展。

目錄

第1章：分析方法和範圍

第2章執行摘要

第3章：市場波動因素、趨勢與範圍

  • 市場相關性展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 產業分析工具
    • 波特五力分析
    • PESTEL 分析

第4章：依產品進行業務分析

  • 細胞治療用人源原料市場：產品特異性波動分析
  • 細胞培養基
    • 細胞培養基市場估算與預測（2021-2033）
  • 細胞培養用血清
    • 細胞培養血清市場估算與預測（2021-2033）
  • 細胞培養添加劑
    • 細胞培養添加劑市場估計與預測（2021-2033）
    • 蛋白質
    • 生長因子
    • 核苷酸
    • 其他添加物
  • 試劑和緩衝溶液
    • 試劑和緩衝液市場估算和預測（2021-2033 年）
  • 其他原料
    • 其他原料市場估算與預測（2021-2033 年）

第5章 依最終用途進行業務分析

  • 細胞治療用人源原料市場：依最終用途分類的波動分析。
  • 生物製藥和製藥公司
    • 生物製藥和製藥公司市場估算和預測（2021-2033 年）
  • 合約研發/合約行銷
    • CRO/CMO市場市場估算與預測（2021-2033年）
  • 學術和研究機構
    • 學術和研究機構市場估算和預測（2021-2033 年）

第6章：按地區分類的業務分析

  • 細胞治療用人源性原料市場佔有率：按地區分類（2025-2033 年）
  • 北美洲
    • 北美細胞治療人源原料市場（2021-2033 年）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲細胞治療人源原料市場（2021-2033 年）
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區人源細胞治療原料市場（2021-2033）
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 拉丁美洲細胞治療人源原料市場（2021-2033 年）
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲細胞治療用人源原料市場（2021-2033 年）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭情勢

  • 公司分類
  • 策略藍圖
  • 企業市場分析/市佔率分析（2025 年）
  • 公司簡介/列表
    • Thermo Fisher Scientific, Inc
    • Merck KGaA
    • Actylis
    • ACROBiosystems
    • STEMCELL Technologies
    • Grifols, SA
    • Charles River Laboratories
    • RoosterBio, Inc.
    • PromoCell GmbH
    • Danaher
    • BioIVT
    • GeminiBio
    • Akron Biotech
    • AllCells
    • CGT Global
Product Code: GVR-4-68040-185-7

Cell Therapy Human Raw Materials Market Summary

The global cell therapy human raw materials market was size valued at USD 4.37 billion in 2025 and is projected to reach USD 16.79 billion by 2033, expanding at a CAGR of 18.44% from 2026 to 2033. The increasing prevalence of chronic diseases such as cancer, diabetes, & autoimmune disorders, the growing demand for regenerative and personalized medicines, rising R&D activities, and increasing investments are anticipated to boost the cell therapy human raw materials market over the forecast period.

Global Cell Therapy Human Raw Materials Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the cell therapy human raw materials market on the basis of products, end use, and region.

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Cell Culture Media
  • Cell Culture Sera
  • Cell Culture Supplements
    • Proteins
    • Growth Factors
    • Nucleotides
    • Other Supplements
  • Reagents & Buffers
  • Other Raw Materials
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Biopharmaceutical & Pharmaceutical Companies
  • CROs & CMOs
  • Academic & Research Institutions
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Product
    • 1.1.2. End Use
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. MARKET DRIVER ANALYSIS
      • 3.2.1.1. Rapid growth of the cell therapy pipeline
      • 3.2.1.2. Expansion of regenerative medicine and personalized medicine
      • 3.2.1.3. Growing prevalence of immune-related disorders
    • 3.2.2. MARKET RESTRAINT ANALYSIS
      • 3.2.2.1. Ethical concerns related to stem cell research
      • 3.2.2.2. High cost associated with the production and procurement of raw materials
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

  • 4.1. Cell Therapy Human Raw Materials Market: Product Movement Analysis
  • 4.2. Cell Culture Media
    • 4.2.1. Cell culture media market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.3. Cell Culture Sera
    • 4.3.1. Cell culture sera market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4. Cell Culture Supplements
    • 4.4.1. Cell culture supplements market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Proteins
      • 4.4.2.1. Proteins market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Growth Factors
      • 4.4.3.1. Growth factors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Nucleotides
      • 4.4.4.1. Nucleotides market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Other Supplements
      • 4.4.5.1. Other supplements market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Reagents & Buffers
    • 4.5.1. Reagents & buffers market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6. Other Raw Materials
    • 4.6.1. Other raw materials market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. End Use Group Business Analysis

  • 5.1. Cell Therapy Human Raw Materials Market: End Use Movement Analysis
  • 5.2. Biopharmaceutical & Pharmaceutical Companies
    • 5.2.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.3. CROs & CMOs
    • 5.3.1. CROS & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4. Academic & Research Institutions
    • 5.4.1. Academic & research institutions market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Cell Therapy Human Raw Materials Share By Region, 2025 & 2033
  • 6.2. North America
    • 6.2.1. North America Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Competitive Scenario
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. Target Disease Prevalence
      • 6.2.2.5. U.S. Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Competitive Scenario
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Target Disease Prevalence
      • 6.2.3.5. Canada Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Competitive Scenario
      • 6.2.4.3. Regulatory Framework
      • 6.2.4.4. Target Disease Prevalence
      • 6.2.4.5. Mexico Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Target Disease Prevalence
      • 6.3.2.5. UK Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Target Disease Prevalence
      • 6.3.3.5. Germany Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Target Disease Prevalence
      • 6.3.4.5. France Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Target Disease Prevalence
      • 6.3.5.5. Italy Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Target Disease Prevalence
      • 6.3.6.5. Spain Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Competitive Scenario
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Target Disease Prevalence
      • 6.3.7.5. Denmark Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Competitive Scenario
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Target Disease Prevalence
      • 6.3.8.5. Sweden Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Competitive Scenario
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Target Disease Prevalence
      • 6.3.9.5. Norway Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Target Disease Prevalence
      • 6.4.2.5. Japan Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Target Disease Prevalence
      • 6.4.3.5. China Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Target Disease Prevalence
      • 6.4.4.5. India Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Target Disease Prevalence
      • 6.4.5.5. Australia Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.6. Thailand
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Target Disease Prevalence
      • 6.4.6.5. Thailand Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.4.7. South Korea
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Target Disease Prevalence
      • 6.4.7.5. South Korea Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Target Disease Prevalence
      • 6.5.2.5. Brazil Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Target Disease Prevalence
      • 6.5.3.5. Argentina Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
  • 6.6. MEA
    • 6.6.1. MEA Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Target Disease Prevalence
      • 6.6.2.5. South Africa Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Target Disease Prevalence
      • 6.6.3.5. Saudi Arabia Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Target Disease Prevalence
      • 6.6.4.5. UAE Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Target Disease Prevalence
      • 6.6.5.5. Kuwait Cell Therapy Human Raw Materials, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position/Share Analysis, 2025
  • 7.4. Company Profiles/Listing
    • 7.4.1. Thermo Fisher Scientific, Inc
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Merck KGaA
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Actylis
      • 7.4.3.1. Overview
      • 7.4.3.2. Product Benchmarking
      • 7.4.3.3. Strategic Initiatives
    • 7.4.4. ACROBiosystems
      • 7.4.4.1. Overview
      • 7.4.4.2. Product Benchmarking
      • 7.4.4.3. Strategic Initiatives
    • 7.4.5. STEMCELL Technologies
      • 7.4.5.1. Overview
      • 7.4.5.2. Product Benchmarking
      • 7.4.5.3. Strategic Initiatives
    • 7.4.6. Grifols, S.A.
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Charles River Laboratories
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. RoosterBio, Inc.
      • 7.4.8.1. Overview
      • 7.4.8.2. Product Benchmarking
      • 7.4.8.3. Strategic Initiatives
    • 7.4.9. PromoCell GmbH
      • 7.4.9.1. Overview
      • 7.4.9.2. Product Benchmarking
      • 7.4.9.3. Strategic Initiatives
    • 7.4.10. Danaher
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. BioIVT
      • 7.4.11.1. Overview
      • 7.4.11.2. Product Benchmarking
      • 7.4.11.3. Strategic Initiatives
    • 7.4.12. GeminiBio
      • 7.4.12.1. Overview
      • 7.4.12.2. Product Benchmarking
      • 7.4.12.3. Strategic Initiatives
    • 7.4.13. Akron Biotech
      • 7.4.13.1. Overview
      • 7.4.13.2. Product Benchmarking
      • 7.4.13.3. Strategic Initiatives
    • 7.4.14. AllCells
      • 7.4.14.1. Overview
      • 7.4.14.2. Product Benchmarking
      • 7.4.14.3. Strategic Initiatives
    • 7.4.15. CGT Global
      • 7.4.15.1. Overview
      • 7.4.15.2. Product Benchmarking
      • 7.4.15.3. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America cell therapy human raw materials market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 4 North America cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 5 U.S. cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 6 U.S. cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 7 Canada cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 8 Canada cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Mexico cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 10 Mexico cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Europe cell therapy human raw materials market, by region, 2021 - 2033 (USD Million)
  • Table 12 Europe cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 13 Europe cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 14 Germany cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 15 Germany cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 16 UK cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 17 UK cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 18 France cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 19 France cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 20 Italy cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 21 Italy cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 22 Spain cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 23 Spain cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Denmark cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 25 Denmark cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 26 Sweden cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 27 Sweden cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Norway cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 29 Norway cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 30 Asia Pacific cell therapy human raw materials market, by region, 2021 - 2033 (USD Million)
  • Table 31 Asia Pacific cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 32 Asia Pacific cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 33 China cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 34 China cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 35 Japan cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 36 Japan cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 37 India cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 38 India cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 39 South Korea cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 40 South Korea cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Australia cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 42 Australia cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Thailand cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 44 Thailand cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 45 Latin America cell therapy human raw materials market, by region, 2021 - 2033 (USD Million)
  • Table 46 Latin America cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Latin America cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 48 Brazil cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 49 Brazil cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Argentina cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 51 Argentina cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 52 MEA cell therapy human raw materials market, by region, 2021 - 2033 (USD Million)
  • Table 53 MEA cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 54 MEA cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 55 South Africa cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 56 South Africa cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 57 Saudi Arabia cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 58 Saudi Arabia cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 59 UAE cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 60 UAE cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)
  • Table 61 Kuwait cell therapy human raw materials market, by product, 2021 - 2033 (USD Million)
  • Table 62 Kuwait cell therapy human raw materials market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Cell therapy human raw materials market: market outlook
  • Fig. 9 Cell therapy human raw materials competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Cell therapy human raw materials market driver impact
  • Fig. 15 Cell therapy human raw materials market restraint impact
  • Fig. 16 Cell therapy human raw materials market strategic initiatives analysis
  • Fig. 17 Cell therapy human raw materials market: product movement analysis
  • Fig. 18 Cell therapy human raw materials market: product outlook and key takeaways
  • Fig. 19 Product market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Cell culture media market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Cell culture sera market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Cell culture supplements market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Proteins market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Growth factors market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Nucleotides market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 Other supplements market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Reagents & buffers market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Other raw materials market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Cell therapy human raw materials market: end use movement analysis
  • Fig. 30 Cell therapy human raw materials market: end use outlook and key takeaways
  • Fig. 31 Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 CROs & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Academic & research facilities market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 34 North America cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 U.S. cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Canada cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Mexico cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Europe cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 UK cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Germany cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 France cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Italy cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Spain cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Denmark cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Sweden cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Norway cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Asia Pacific cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 China cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Japan cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 India cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Thailand cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 South Korea cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Australia cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Latin America cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Brazil cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Argentina cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Middle East and Africa cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 South Africa cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Saudi Arabia cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 UAE cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Kuwait cell therapy human raw materials market estimates and forecasts, 2021 - 2033 (USD Million)